Zilucoplan sodium - Generic Drug Details

What are the generic sources for zilucoplan sodium and what is the scope of freedom to operate?

Zilucoplan sodium is the generic ingredient in one branded drug marketed by Ucb Inc and is included in one NDA. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Zilucoplan sodium has one hundred and forty-three patent family members in thirty-two countries.

One supplier is listed for this compound.

Summary for zilucoplan sodium

International Patents:	143
US Patents:	9
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
DailyMed Link:	zilucoplan sodium at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for zilucoplan sodium

Constraining patent/regulatory exclusivity:

TREATMENT OF GENERALIZED MYASTHENIA GRAVIS (GMG) IN ADULT PATIENTS WHO ARE ANTI-ACETYLCHOLINE RECEPTOR (ACHR) ANTIBODY POSITIVE

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for zilucoplan sodium

Drug Class	Complement Inhibitor
Mechanism of Action	Complement Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for zilucoplan sodium

L04AJ	Complement inhibitors
L04A	IMMUNOSUPPRESSANTS
L04	IMMUNOSUPPRESSANTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for zilucoplan sodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ucb Inc	ZILBRYSQ	zilucoplan sodium	SOLUTION;SUBCUTANEOUS	216834-002	Oct 17, 2023		RX	Yes	Yes
Ucb Inc	ZILBRYSQ	zilucoplan sodium	SOLUTION;SUBCUTANEOUS	216834-002	Oct 17, 2023		RX	Yes	Yes			Y
Ucb Inc	ZILBRYSQ	zilucoplan sodium	SOLUTION;SUBCUTANEOUS	216834-003	Oct 17, 2023		RX	Yes	Yes
Ucb Inc	ZILBRYSQ	zilucoplan sodium	SOLUTION;SUBCUTANEOUS	216834-001	Oct 17, 2023		RX	Yes	Yes				Y
Ucb Inc	ZILBRYSQ	zilucoplan sodium	SOLUTION;SUBCUTANEOUS	216834-001	Oct 17, 2023		RX	Yes	Yes			Y
Ucb Inc	ZILBRYSQ	zilucoplan sodium	SOLUTION;SUBCUTANEOUS	216834-003	Oct 17, 2023		RX	Yes	Yes			Y	Y
Ucb Inc	ZILBRYSQ	zilucoplan sodium	SOLUTION;SUBCUTANEOUS	216834-002	Oct 17, 2023		RX	Yes	Yes				Y

International Patents for zilucoplan sodium

Country	Patent Number	Title	Estimated Expiration
Singapore	11201804721S
France	24C1022
Croatia	P20200508
San Marino	T202100688
Cyprus	1122227
Hungary	E055931
Cyprus	1123031

Supplementary Protection Certificates for zilucoplan sodium

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3154561	C03154561/01	Switzerland		FUSION; FORMER OWNER: RA PHARMACEUTICALS, INC., US
3154561	CA 2024 00021	Denmark		PRODUCT NAME: ZILUCOPLAN; REG. NO/DATE: EU/1/23/1764 20231204
3154561	C202430020	Spain		PRODUCT NAME: ZILUCOPLAN; NATIONAL AUTHORISATION NUMBER: EU/1/23/1764; DATE OF AUTHORISATION: 20231201; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/23/1764; DATE OF FIRST AUTHORISATION IN EEA: 20231201
3154561	CR 2024 00021	Denmark		PRODUCT NAME: ZILUCOPLAN; REG. NO/DATE: EU/1/23/1764 20231204
3154561	C20240015	Finland
3154561	LUC00343	Luxembourg		PRODUCT NAME: ZILUCOPLAN; AUTHORISATION NUMBER AND DATE: EU/1/23/1764 20231204
3154561	2490016-9	Sweden		PRODUCT NAME: ZILUCOPLAN; REG. NO/DATE: EU/1/23/1764 20231204

Market Dynamics and Financial Trajectory for Zilucoplan Sodium

Last updated: February 19, 2026

What Is the Developments Timeline and Approval Status?

Zilucoplan sodium is a complement inhibitor developed by UCB Pharma targeting rare autoimmune diseases such as generalized myasthenia gravis (gMG). As of early 2023, it remains in clinical trial phases with no FDA or EMA approval.

• Phase: Completed Phase 2 trials; Phase 3 recruitment ongoing.
• Key Data: Positive Phase 2 results in improving muscle strength in gMG patients.
• Projected Approval: Anticipated between 2024 and 2025 based on current trial progress, contingent on successful trial outcomes and regulatory review.

How Does Market Size and Competitive Landscape Look?

The primary market for zilucoplan sodium is in autoimmune neuromuscular disorders, notably:

• Generalized Myasthenia Gravis (gMG): Affects roughly 60,000 patients in the U.S. and Europe.
• Other indications: Potential for expansion into diseases such as atypical hemolytic uremic syndrome (aHUS).

Key competitors include:

Compound	Developer	Phase	Mechanism	Marketed Status
Eculizumab	Alexion (AstraZeneca)	Approved	Complement inhibitor	Approved for gMG, aHUS
Ravulizumab	Alexion	Approved	Complement inhibitor	Approved for similar indications
Zilucoplan	UCB Pharma	Phase 3	Peptide complement inhibitor	Not approved

The current competitive landscape features approved complement inhibitors, which have established market presence. Zilucoplan's key differentiator is the subcutaneous administration route and potentially improved safety profile, aiming for better patient adherence.

What Are the Financial Projections Based on Development Progress?

Financial forecasts hinge on multiple factors including trial success, approval timing, and market penetration:

• Market size estimate: The global gMG market could reach USD 2.2 billion by 2026.
• Pricing assumptions: Estimated USD 150,000 annually per patient based on similar therapies like eculizumab.
• Market penetration: Expected to capture 30-50% of eligible patients within five years post-approval.
• Potential revenue: Approaching USD 600-1 billion, assuming half of the projected patient population is treated.

Cost considerations:

• R&D investments: Estimated USD 300-500 million to complete Phase 3.
• Commercialization costs: Marketing and distribution costs estimated USD 50-100 million annually post-launch.

Risk factors include unanticipated trial results, regulatory delays, or strong competition from longer-established drugs.

What Regulatory and Market Challenges Could Impact Commercialization?

• Regulatory hurdles: Approval hinges on meeting efficacy and safety thresholds established in Phase 3 data.
• Market access: Payers may negotiate high discounts or demand robust clinical data to justify premium pricing.
• Competitive pressure: Eculizumab’s long-market presence may limit pricing flexibility.
• Manufacturing: Scaling up peptide synthesis to meet demand could delay availability.

How Do Intellectual Property and Patent Positions Shape Financial Outlook?

• Patent landscape: UCB holds patents extending into the late 2030s covering the peptide structure, administration methods, and formulation.
• Patent challenges: No significant legal disputes reported as of 2023.
• Implications: Patents can secure market exclusivity, enabling premium pricing strategies and safeguarding revenue projections.

Summary of Market and Financial Outlook

Factor	Status	Implication
Development stage	Phase 3 trials ongoing	Near-term commercialization possible in 2024–2025
Market size	USD 2.2 billion (target)	Large enough for profitable commercialization
Competition	Established complement inhibitors	Puts pressure on pricing and market share
Revenues	USD 600 million to USD 1 billion	Likely achievable post-approval with rapid adoption
Risks	Regulatory delays, market access	Could reduce revenue potential

Key Takeaways

• Zilucoplan sodium remains in late-stage clinical development, with potential approval in 2024–2025.
• The target market is sizable, with existing approved drugs setting a competitive benchmark.
• Financial success depends on regulatory approval timing, clinical efficacy, pricing, and payer acceptance.
• Patent protection and manufacturing scale-up are critical for maximizing revenue.
• Market entry will face competition from well-established complement inhibitors, influencing pricing strategies.

FAQs

What are the primary clinical benefits of zilucoplan sodium over existing therapies?

It offers a subcutaneous route of administration and potentially improved safety and convenience, which may enhance patient adherence.

When is commercialization expected?

Conditional on trial outcomes, regulatory review is anticipated to happen between 2024 and 2025.

What are the biggest risks to market success?

Failure to demonstrate superior efficacy or safety, regulatory delays, or pricing pressures from payers.

How does the competitive landscape affect potential pricing?

Existing therapies like eculizumab command high prices; zilucoplan's penetration may require competitive pricing strategies or differentiation in safety or convenience.

What is the potential market size for zilucoplan sodium?

Estimated at roughly USD 2.2 billion globally for gMG alone, with scope for expansion to other complement-mediated disorders.

---

References

[1] International Myasthenia Gravis Foundation. (2022). Myasthenia Gravis Overview. https://myasthenia.org/medical-professionals/overview

[2] GlobalData. (2023). Autoimmune Disease Market Report. https://www.globaldata.com/store/report/autoimmune-diseases-market-analysis/

[3] UCB Pharma. (2023). Zilucoplan Clinical Development Overview. Company Reports.

[4] EvaluatePharma. (2023). 2023 World Preview: Drugs & Biologics. https://evalueserve.com/

[5] U.S. Food and Drug Administration. (2023). Guidance for Industry: Clinical Data Needed to Support the Approval of a New Drug. https://www.fda.gov